NASDAQ · NTRA
Natera, Inc.
$436.00+$11.58 (+2.73%)
Natera, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.32% below the high.
Loading market information…
NYSE · DGX · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Quest Diagnostics Incorporated’s quoted price sits in the upper half of its reported 52-week range, 0.08% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Quest Diagnostics Incorporated’s forward annual dividend is $3.44 per share, paid quarterly. The forward yield is 1.36% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Quest Diagnostics Incorporated’s next earnings report is currently expected on Feb 9, 2027, with estimated earnings per share of $2.68. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Quest Diagnostics Incorporated’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:16 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2025 | Jul 22, 2025 | $2.62+1.95% vs estimate | $2.76B+1.32% vs estimate |
|---|
| Q1 2025 | Apr 22, 2025 | $2.21+2.79% vs estimate | $2.65B+0.83% vs estimate |
|---|
| Q4 2024 | Jan 30, 2025 | $2.23+1.83% vs estimate | $2.62B+1.65% vs estimate |
|---|
KEEP COMPARING
$436.00+$11.58 (+2.73%)
Natera, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.32% below the high.
$290.06+$1.27 (+0.44%)
Illumina, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.24% below the high.
$368.16+$7.91 (+2.2%)
Labcorp Holdings Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.77% below the high.
$185.31+$2.72 (+1.49%)
Guardant Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.0% below the high.
$165.78+$0.45 (+0.27%)
Revvity, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.94% below the high.
€90.15-€0.85 (-0.93%)
bioMérieux S.A.’s quoted price sits in the lower half of its reported 52-week range, 22.35% below the high.
$50.34+$0.01 (+0.02%)
Qiagen N.V.’s quoted price sits in the upper half of its reported 52-week range, 12.94% below the high.
$158.92+$1.04 (+0.66%)
GRAIL Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.54% below the high.
THE ANALYST VIEW
34 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 6 contributors · Median target $260.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
